How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.


The clinical efficacy of JAK2-inhibitors in patients with myelofibrosis, that involves a rapid and massive reduction of spleen enlargement and improvement of clinical symptoms, is not accompanied by significant modifications of hematologic parameters nor of the burden of JAK2V617F allele. Furthermore, clinical improvement has been reported to occur… (More)
DOI: 10.1016/j.leukres.2009.06.001